Subtopic Deep Dive

← Pediatric health and respiratory diseases

Immunostimulants and Immunomodulation for Pediatric Respiratory Diseases
Research Guide

What is Immunostimulants and Immunomodulation for Pediatric Respiratory Diseases?

Immunostimulants and immunomodulation for pediatric respiratory diseases involves bacterial lysates, probiotics, and adjuvants like OM-85 to enhance mucosal immunity and prevent recurrent respiratory tract infections (RTIs) in children.

Research centers on OM-85 bacterial lysate and similar immunostimulants to reduce wheezing episodes and asthma exacerbations in children (de Boer et al., 2020, 68 citations). Clinical trials demonstrate efficacy in high-risk groups, including children with Down syndrome showing immune dysregulation (Huggard et al., 2020, 118 citations). Over 20 papers since 2013 explore mechanisms like interferon-β modulation and microbiome dysbiosis links to asthma (Hufnagl et al., 2020, 340 citations).

Curated Papers

Key Challenges

Why It Matters

Bacterial lysates like OM-85 reduce recurrent RTIs in children, lowering antibiotic use and hospitalization rates (Esposito et al., 2019, 53 citations; Koatz et al., 2016, 70 citations). In allergic rhinitis and asthma, they provide clinical and immunological benefits, preserving lung function (Koatz et al., 2016). For Down syndrome children with innate and adaptive immune defects, targeted immunomodulation addresses vulnerabilities to respiratory pathogens (Huggard et al., 2020). Systematic reviews confirm prevention of wheezing via respiratory virus modulation (de Boer et al., 2020).

Key Research Challenges

Heterogeneity in Clinical Responses

Pediatric trials show variable efficacy of OM-85 across age groups and comorbidities like Down syndrome (Esposito et al., 2019). Differences in baseline microbiome dysbiosis complicate outcomes (Hufnagl et al., 2020). Meta-analyses highlight need for standardized dosing (de Boer et al., 2020).

Mechanisms of Innate-Adaptive Crosstalk

OM-85 modulates interferon-β and inflammasome activity, but pediatric-specific pathways remain unclear (Dang et al., 2017). Mucosal antibody enhancement post-oral bacterial extract needs innate-adaptive linkage studies (Pasquali et al., 2014). Gut-lung axis dysbiosis requires mechanistic validation (Hufnagl et al., 2020).

Safety in High-Risk Pediatric Groups

Immunostimulants risk overactivation in immune-dysregulated children with Down syndrome (Huggard et al., 2020). Long-term data on lysates like OM-85 in recurrent RTI prevention is limited (Esposito et al., 2020). Phase IV trials note mild adverse events but call for broader safety profiling (Esposito et al., 2019).

Essential Papers

Dysbiosis of the gut and lung microbiome has a role in asthma

Karin Hufnagl, Isabella Pali‐Schöll, Franziska Roth‐Walter et al. · 2020 · Seminars in Immunopathology · 340 citations

Immune Dysregulation in Children With Down Syndrome

Dean Huggard, Derek G. Doherty, Eleanor J. Molloy · 2020 · Frontiers in Pediatrics · 118 citations

Down syndrome (DS) is the most common genetic syndrome associated with immune defects. The extent of immune dysregulation in DS is substantial, spanning the innate and adaptive systems and includin...

Enhanced Mucosal Antibody Production and Protection against Respiratory Infections Following an Orally Administered Bacterial Extract

Christian Pasquali, Olawale Salami, Manisha Taneja et al. · 2014 · Frontiers in Medicine · 81 citations

Secondary bacterial infections following influenza infection are a pressing problem facing respiratory medicine. Although antibiotic treatment has been highly successful over recent decades, fatali...

Clinical and Immunological Benefits of OM-85 Bacterial Lysate in Patients with Allergic Rhinitis, Asthma, and COPD and Recurrent Respiratory Infections

Ana M Koatz, Noemí A. Coe, Alberto Cicerán et al. · 2016 · Lung · 70 citations

Bacterial lysate therapy for the prevention of wheezing episodes and asthma exacerbations: a systematic review and meta-analysis

Geertje M. de Boer, Jakub Żółkiewicz, Konrad Piotr Strzelec et al. · 2020 · European Respiratory Review · 68 citations

Wheezing and asthma are a growing cause of morbidity in children and adults. Treatment is aimed at prevention of disease exacerbations and preservation of lung function. Respiratory viruses are inv...

OM-85 is an immunomodulator of interferon-β production and inflammasome activity

Anh Thu Dang, Christian Pasquali, Kristina Ludigs et al. · 2017 · Scientific Reports · 60 citations

Bacterial Lysates as Immunotherapies for Respiratory Infections: Methods of Preparation

Norma Suárez, Florencia Ferrara, Analía Rial et al. · 2020 · Frontiers in Bioengineering and Biotechnology · 58 citations

Bacterial lysates, prepared from the microorganisms most frequently involved in human Respiratory Tract Infections (RTIs) have been in the market for several decades, and at present, several differ...

Reading Guide

Foundational Papers

Start with Pasquali et al. (2014, 81 citations) for mucosal antibody mechanisms via oral bacterial extracts; De Benedetto and Sevieri (2013) for OM-85 RTI prevention state-of-the-art.

Recent Advances

Study Hufnagl et al. (2020, 340 citations) on microbiome dysbiosis in asthma; de Boer et al. (2020, 68 citations) meta-analysis on lysates for wheezing; Kaczyńska et al. (2022, 45 citations) on allergic disease immunomodulation.

Core Methods

Core techniques: bacterial lysate preparation (Suárez et al., 2020), phase IV RCTs like Esposito et al. (2019), systematic reviews/meta-analyses (de Boer et al., 2020), and inflammasome/interferon assays (Dang et al., 2017).

How PapersFlow Helps You Research Immunostimulants and Immunomodulation for Pediatric Respiratory Diseases

Discover & Search

PapersFlow's Research Agent uses searchPapers and citationGraph to map OM-85 trials from Esposito et al. (2019), revealing 53 citing works on pediatric RTIs. exaSearch uncovers microbiome links like Hufnagl et al. (2020, 340 citations); findSimilarPapers extends to de Boer meta-analysis (2020).

Analyze & Verify

Analysis Agent applies readPaperContent to extract OM-85 efficacy data from Koatz et al. (2016), then verifyResponse with CoVe checks claims against Esposito trial (2019). runPythonAnalysis performs meta-analysis on recurrence rates from de Boer et al. (2020) using pandas for GRADE evidence grading on wheezing reduction.

Synthesize & Write

Synthesis Agent detects gaps in Down syndrome immunomodulation (Huggard et al., 2020) and flags contradictions in microbiome effects (Hufnagl et al., 2020). Writing Agent uses latexEditText, latexSyncCitations for OM-85 review drafts, and latexCompile for publication-ready tables; exportMermaid visualizes gut-lung axis pathways from Pasquali et al. (2014).

Use Cases

"Run meta-analysis on OM-85 reducing RTI episodes in children under 5."

Research Agent → searchPapers('OM-85 pediatric RTI') → Analysis Agent → runPythonAnalysis(pandas forest plot on de Boer 2020 + Esposito 2019 data) → GRADE-graded summary statistics with effect sizes.

"Draft LaTeX review on bacterial lysates for asthma prevention."

Synthesis Agent → gap detection(de Boer 2020, Koatz 2016) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(10 OM-85 papers) → latexCompile(PDF with tables from Hufnagl 2020 microbiome data).

"Find code for analyzing pediatric immune biomarkers from RTI trials."

Research Agent → paperExtractUrls(Huggard 2020) → paperFindGithubRepo → Code Discovery → githubRepoInspect(R scripts for T/B cell anomaly stats) → runPythonAnalysis(replicate in sandbox).

Automated Workflows

Deep Research workflow conducts systematic review of 50+ OM-85 papers: searchPapers → citationGraph → DeepScan(7-step verify on Esposito 2019 trial) → structured report with GRADE scores. Theorizer generates hypotheses on gut-lung dysbiosis from Hufnagl (2020) + Pasquali (2014), chaining readPaperContent → gap detection. DeepScan applies CoVe checkpoints to meta-analyses like de Boer (2020) for hallucination-free efficacy claims.

Try Doxa for Immunostimulants and Immunomodulation for Pediatric Respiratory Diseases Research

Frequently Asked Questions

What defines immunostimulants for pediatric respiratory diseases?

Immunostimulants like OM-85 bacterial lysates enhance mucosal immunity to prevent recurrent RTIs and wheezing in children (de Boer et al., 2020).

What are key methods in this research?

Methods include oral bacterial extracts for mucosal antibodies (Pasquali et al., 2014), OM-85 for interferon-β modulation (Dang et al., 2017), and meta-analyses of lysate prevention trials (de Boer et al., 2020).

What are the most cited papers?

Top papers are Hufnagl et al. (2020, 340 citations) on gut-lung dysbiosis in asthma; Huggard et al. (2020, 118 citations) on Down syndrome immune defects; Pasquali et al. (2014, 81 citations) on bacterial extract protection.

What open problems exist?

Challenges include pediatric-specific mechanisms of innate-adaptive crosstalk (Dang et al., 2017), long-term safety in high-risk groups (Huggard et al., 2020), and standardizing lysates across microbiomes (Suárez et al., 2020).